Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia

Journal of Clinical Virology

Volumn 45, Issue 2, 2009, Pages 85-89

  Gustavsson, Inger ^a   Juko Pecirep, Ivana ^a   Backlund, Ingrid ^b   Wilander, Erik ^a,b   Gyllensten, Ulf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervical carcinoma; Human papillomavirus; Real time PCR

Indexed keywords

ARTICLE; ASSAY; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; GENE SEQUENCE; HIGH RISK POPULATION; HPVIR ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRID CAPTURE 2; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIXED INFECTION; NUCLEOTIDE SEQUENCE; PAPANICOLAOU TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN; VIRUS TYPING; WART VIRUS;

CERVIX UTERI; FEMALE; HUMANS; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 66049138416     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.04.012     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Bergstrom R., Sparen P., and Adami H.O. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 81 (1999) 159-166
3. Anttila A., Pukkala E., Soderman B., Kallio M., Nieminen P., and Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 83 (1999) 59-65
4. Horn P.L., Lowell D.M., LiVolsi V.A., and Boyle C.A. Reproducibility of the cytologic diagnosis of human papillomavirus infection. Acta Cytol 29 (1985) 692-694
5. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 796-802
6. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
7. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
8. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., et al. HPV testing in primary screening of older women. Br J Cancer 81 (1999) 554-558
9. Schiffman M., Herrero R., Hildesheim A., Sherman M.E., Bratti M., Wacholder S., et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283 (2000) 87-93
10. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84 (2001) 1616-1623
11. Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88 (2003) 1570-1577
12. Josefsson A.M., Magnusson P.K., Ylitalo N., Sorensen P., Qwarforth-Tubbin P., Andersen P.K., et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2189-2193
13. Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Ponten J., et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2194-2198
14. Healey S.M., Aronson K.J., Mao Y., Schlecht N.F., Mery L.S., Ferenczy A., et al. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. Sex Transm Dis 28 (2001) 694-700
15. Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., and Chu T.Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 76 (2002) 41-47
16. Hernandez D., Ornelas L., Guido M., Apresa T., Alvarado I., Salcedo M., et al. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol 90 (2003) 310-317
17. Dalstein V., Riethmuller D., Pretet J.L., Le Bail Carval K., Sautiere J.L., Carbillet J.P., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 106 (2003) 396-403
18. Moberg M., Gustavsson I., and Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 112 (2004) 854-859
19. Moberg M., Gustavsson I., Wilander E., and Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 92 (2005) 891-894
20. Wright Jr. T.C., Cox J.T., Massad L.S., Twiggs L.B., and Wilkinson E.J. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 287 (2002) 2120-2129
21. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., and Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96 (2004) 280-293
22. Carozzi F., Bisanzi S., Sani C., Zappa M., Cecchini S., Ciatto S., et al. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 45 (2007) 364-369
23. Soderlund-Strand A., Rymark P., Andersson P., Dillner J., and Dillner L. Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 43 (2005) 3260-3266
24. Kulmala S.M., Syrjanen S., Shabalova I., Petrovichev N., Kozachenko V., Podistov J., et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 42 (2004) 2470-2475
25. Moberg M., Gustavsson I., and Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol 41 (2003) 3221-3228
26. Josefsson A., Livak K., and Gyllensten U. Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay. J Clin Microbiol 37 (1999) 490-496
27. Poljak M., Marin I.J., Seme K., and Vince A. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 25 Suppl. 3 (2002) S89-S97